Coffee consumption and glucose tolerance in humans.

Acute effects of coffee and major coffee components on glucagon-like peptide 1 response and glucose tolerance in humans.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON23240

Enrollment

Registered

2007-09-06

Start date

2007-08-15

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus type 2 (DM type II)

Interventions

All participants will receive four treatments in random order, on four different days: 1. Decaffeinated coffee

2. Chlorogenic acid. 3. Trigonelline. 4. Mannitol (placebo). All treatments will be ingested before an oral glucose tolerance test. Blood samples will be taken on 7 occasions on each study day. T

Eligibility

Inclusion criteria

Inclusion criteria: 1. Apparently healthy males; Acute effects of coffee and major coffee components on glucagon-like peptide 1 response and glucose tolerance in humans; 2. Age at screening: 18 years and above; 3. Body mass index (BMI) between 25.0 and 35.0 kg/m2; 4. Regular coffee consumer; 5. Willing to restrict coffee consumption during the study to max. 1 cup per day; 6. Voluntary participation; 7. Willing not to be blood or plasmaferese donor from 4 weeks before the start of the study until the end of study.

Exclusion criteria

Exclusion criteria: 1. Women; 2. Smokers; 3. Diabetics; 4. Blood sampling is considered too difficult (assessed during pre-study screening); 5. Any chronic or acute disease; 6. Hypertension criteria for moderate hypertension WHO 2003; 7. Medical history or surgical events known to interfere with the study; 8. Alcohol consumption > 28 consumptions per week; 9. Self reported weight loss or gain > 2 kg in the month prior to screening; 10. Any special diet; 11. Participation in any other intervention trial up to 3 months before and during this study; 12. Use of medication known to interfere with the study outcome; 13. Exercising more than 4 hours vigorously per week.

Design outcomes

Primary

Measure	Time frame
Glucose and insulin concentrations in blood	—

Secondary

Measure	Time frame
Glucagon-like peptide-1 concentrations and dipeptidyl peptidase IV activity in blood	—

Contacts

Public ContactMargreet R. Olthof

De Boelelaan 1085

margreet.olthof@falw.vu.nl+31 205982522

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)